Salix Pharmaceuticals Ltd (SLXP) Tops Q4 EPS by 2c

February 28, 2013 4:36 PM EST Send to a Friend
Salix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q4 EPS of $0.81, $0.02 better than the analyst estimate of $0.79. Revenue for the quarter came in at $198.2 million versus the consensus estimate of $199.41 million.

For earnings history and earnings-related data on Salix Pharmaceuticals Ltd (SLXP) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings

Add Your Comment